Sonoma Pharmaceuticals Enters Manufacturing Agreement
Ticker: SNOA · Form: 8-K · Filed: Apr 9, 2026 · CIK: 0001367083
Sentiment: neutral
Topics: material-agreement, manufacturing, supply-chain
TL;DR
Sonoma Pharma just signed a new manufacturing deal. Big implications for supply chain.
AI Summary
On April 8, 2026, Sonoma Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a Manufacturing and Supply Agreement. The filing details this agreement as a key event, with the full agreement provided as an exhibit.
Why It Matters
This agreement signifies a strategic step for Sonoma Pharmaceuticals in securing its manufacturing capabilities, which could impact product availability and cost.
Risk Assessment
Risk Level: medium — Manufacturing agreements can carry risks related to production quality, supply chain disruptions, and cost fluctuations.
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Filer of the 8-K
- 0001367083 (company) — CIK number for Sonoma Pharmaceuticals, Inc.
- 2026-04-09 (date) — Filing Date of the 8-K
- 2026-04-08 (date) — Period of Report for the 8-K
FAQ
What is the nature of the Manufacturing and Supply Agreement?
The filing indicates it is a material definitive agreement, with the full text provided as Exhibit 10.1.
When was this agreement entered into?
The agreement is related to the period of report ending April 8, 2026, and the filing was accepted on April 9, 2026.
What is Sonoma Pharmaceuticals, Inc.'s CIK number?
Sonoma Pharmaceuticals, Inc.'s CIK number is 0001367083.
What are the main items reported in this 8-K filing?
The main items reported are Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
Where is Sonoma Pharmaceuticals, Inc. located?
Sonoma Pharmaceuticals, Inc.'s mailing and business address is 5445 CONESTOGA COURT, SUITE 150, BOULDER CO 80301.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2026 regarding Sonoma Pharmaceuticals, Inc. (SNOA).